Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genfar

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...

Research Partnership

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

Generic Differentiation

Even in the cost-led market for generics, differentiated business models evolve

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links